NASDAQ NMS - GLOBAL MARKET · GNPX

-9.33% · -$0.3500 · Vol 248.9K

Market closed · last close 4:00 PM ET · price as of 19:56:58 ET

Genprex Inc

Biotechnology

$3.40

Card

Relationship Map

Follow $GNPX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $GNPX by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measured

Thu Sep 24 · market closed · Markets closed · resumes Fri 9:30 ET · GNPX

Methodology

Sentiment absence reason unknown

GNPX

Genprex Inc

Thu Sep 24 · market closed · Markets closed · resumes Fri 9:30 ET

55/100

Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

55/ 100

Veridion Score

Middle range · MEDIUM confidence · 5 of 6 factors measured

Sovereign · $25/mo

See why this score moved.

· Factor breakdown with raw signals
· Day-over-day delta + driver
· Factor coverage readout
· Valuation · hype · market flow
· Pro Chart event markers
· Score history + alerts

Start Sovereign · $25/mo →

Cancel anytime · or Reserve · $79/mo

Confidence: MEDIUM · 5 of 6 factors measured · Thu Sep 24 · market closed · Markets closed · resumes Fri 9:30 ET

Share on X →

Veridion Score History · 90D

AI Analysis

Sovereign

Why is GNPX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.

Catalyst calendar

What can move GNPX next.

Earnings, ratings, disclosures, volume, and score-history events. Every row needs a dated receipt.

Congress / Score

Upcoming

No dated upcoming catalyst is present in the current source window.

Recent

Sep 24
Score
Score moved +15
40/Lower range -> 55/Middle range
Veridion score historySource
Feb 5
CongressChecking access
Tim Moore purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Dec 31
CongressChecking access
Hon. Tim Moore sale disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Dec 18
CongressChecking access
Tim Moore purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Nov 7
CongressChecking access
Tim Moore purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access
Oct 29
CongressChecking access
Tim Moore purchase disclosed
Checking the receipt access included with your plan.
STOCK Act filingChecking access

About Genprex Inc

PHARMACEUTICAL PREPARATIONS

Listed since

2018

Employees

Country

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Company website →

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open

$3.66

Day high

$3.66

Day low

$3.36

Previous close

$3.75

52W high